or Try an Advanced Search...

    Liver Disease Stocks List

    Symbol Grade Name % Change
    GNFT F GENFIT S.A. -1.62
    BFRG F Bullfrog AI Holdings, Inc -1.48
    NTLA F Intellia Therapeutics, Inc. 5.11
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic Health Information Services
    Related Stock Lists: Medicine Hepatitis Non Alcoholic Fatty Liver Disease Steatohepatitis Alcohol Amyloid Amyloidosis Antitrypsin Deficiency Artificial Intelligence Autoimmune Disease Biology Biopharmaceutical Biotechnology CRISPR Cas9 Cell Product Chimeric Antigen Receptor Chimeric Antigen Receptor T Cell Chronic Liver Disease Clinical Management

    Related ETFs - A few ETFs which own one or more of the above listed Liver Disease stocks.

    Symbol Grade Name Weight
    BBH D Market Vectors Biotech ETF 14.47
    IBBQ D Invesco Nasdaq Biotechnology ETF 13.44
    IBB D iShares Nasdaq Biotechnology Index Fund 13.25
    BIB F ProShares Ultra Nasdaq Biotechnology 10.11
    BIS B ProShares UltraShort Nasdaq Biotechnology 9.01
    View all Liver Disease ETFs...
    Compare ETFs
    Compare BBH to BIS Compare BBH to IBBQ Compare IBB to BIS

        Liver Disease Stocks Recent News

        Date Stock Title
        Nov 21 GNFT Genfit Balances Ipsen Partnership With High-Risk Pipeline Ambitions
        Nov 19 NTLA Intellia Therapeutics Announces Promising CRISPR Therapy Results
        Nov 19 NTLA ReCode to secure funds for cystic fibrosis gene correction treatments
        Nov 19 NTLA Intellia Therapeutics price target lowered to $70 from $80 at Wells Fargo
        Nov 19 NTLA Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade)
        Nov 18 NTLA Intellia’s gene editing therapy shows early potential in rare heart condition
        Nov 18 NTLA CRISPR therapy from Intellia may ameliorate rare heart disorder, data suggest
        Nov 16 NTLA Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis
        Related Industries: Biotechnology Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic Health Information Services
        Related Stock Lists: Medicine Biopharmaceutical Hepatitis Non Alcoholic Fatty Liver Disease Steatohepatitis Alcohol Chronic Liver Diseases Clinical Medicine Coronavirus Drug Development Gilead Sciences Hepatitis B Hepatology Hepatotoxins Lipid Liver Fibrosis Pulmonary Arterial Hypertension Tenofovir Disoproxil Acid Acute Intermittent Porphyria
        Liver Disease

        Liver disease (also called hepatic disease) is a type of damage to or disease of the liver. Whenever the course of the problem lasts long, chronic liver disease ensues.

        More about Liver Disease
        Browse All Tags